These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29277818)

  • 1. Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
    Rades D; Bartscht T; Idel C; Hakim SG
    Anticancer Res; 2018 Jan; 38(1):519-523. PubMed ID: 29277818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer.
    Rades D; Bartscht T; Idel C; Schild SE; Hakim SG
    Anticancer Res; 2018 Jun; 38(6):3653-3656. PubMed ID: 29848723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck.
    Rades D; Seidl D; Wollenberg B; Schild SE; Hakim SG
    Anticancer Res; 2016 Oct; 36(10):5463-5468. PubMed ID: 27798916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot trial of concomitant chemotherapy with paclitaxel and split-course radiotherapy for very advanced squamous cell carcinoma of head and neck.
    Feher O; Martins SJ; Lima CA; Salvajoli JV; Simpson AJ; Kowalski LP
    Head Neck; 2002 Mar; 24(3):228-35. PubMed ID: 11891954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
    Tao Y; Faivre L; Laprie A; Boisselier P; Ferron C; Jung GM; Racadot S; Gery B; Even C; Breuskin I; Bourhis J; Janot F
    Radiother Oncol; 2018 Sep; 128(3):467-471. PubMed ID: 29784451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
    Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
    Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.
    Specenier PM; Van den Weyngaert D; Van Laer C; Weyler J; Van den Brande J; Huizing MT; Dyck J; Schrijvers D; Vermorken JB
    Ann Oncol; 2007 Nov; 18(11):1856-60. PubMed ID: 17823386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
    Kharofa J; Choong N; Wang D; Firat S; Schultz C; Sadasiwan C; Wong S
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):690-5. PubMed ID: 22112556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
    Vormittag L; Lemaire C; Radonjic D; Kornek G; Selzer E
    Strahlenther Onkol; 2012 Mar; 188(3):235-42. PubMed ID: 22318328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study.
    Pergolizzi S; Santacaterina A; Adamo B; Franchina T; Denaro N; Ferraro P; Ricciardi GR; Settineri N; Adamo V
    Radiat Oncol; 2011 Nov; 6():162. PubMed ID: 22108341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck.
    Echevarria MI; Yang GQ; Chen DT; Kirtane K; Russell J; Kish J; Muzaffar J; Otto K; Padhya T; McMullen C; Patel K; Chung CH; Caudell JJ
    Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):341-347. PubMed ID: 37105404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
    Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
    Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.
    Halim AA; Wahba HA; El-Hadaad HA; Abo-Elyazeed A
    Med Oncol; 2012 Mar; 29(1):279-84. PubMed ID: 21279703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer.
    Chitapanarux I; Tharavichitkul E; Kamnerdsupaphon P; Pukanhapan N; Vongtama R
    J Radiat Res; 2013 Nov; 54(6):1110-7. PubMed ID: 23740894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic.
    Curtis KK; Ross HJ; Garrett AL; Jizba TA; Patel AB; Patel SH; Wong WW; Halyard MY; Ko SJ; Kosiorek HE; Foote RL
    Radiat Oncol; 2016 Apr; 11():55. PubMed ID: 27061083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
    Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
    World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
    Milano MT; Vokes EE; Salama JK; Stenson KM; Kao J; Witt ME; Mittal BB; Argiris A; Weichselbaum RR; Haraf DJ
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1096-106. PubMed ID: 15752889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
    Vanderveken OM; Szturz P; Specenier P; Merlano MC; Benasso M; Van Gestel D; Wouters K; Van Laer C; Van den Weyngaert D; Peeters M; Vermorken J
    Oncologist; 2016 Jan; 21(1):59-71. PubMed ID: 26712958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.